Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cytokine adsorption using the cytosorb adsorber is currently investigated to reduce the levels of proinflammatory cytokines in patients with severe sepsis and septic shock. The adsorber is frequently used in series with continuous renal replacement therapy. Up to date, no data on the removal of antibiotic drugs during combined renal replacement therapy and cytokine adsorptive therapy is available. Therefore, we want to investigate
- whether and to what extent antibiotic drugs (piperacillin/tazobactam and imipenem/cilastatin) are removed during combined continuous renal replacement therapy and cytosorb adsorption in patients with severe sepsis and septic shock
Patients in this trial are undergoing renal replacement therapy as part of their routine care. Thus, this is an observational trial.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Piperacillin/Tazobactam | Critically ill patients teated with piperacillin/tazobactam undergoing renal replacement therapy and cytosorb absorption during sepsis |
| |
| Imipenem/Cilastatin | Critically ill patients teated with imipenem/cilastatin undergoing renal replacement therapy and cytosorb absorption during sepsis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Monitoring of antibiotic drug removal | Other | No study specific intervention will be performed |
|
| Measure | Description | Time Frame |
|---|---|---|
| Removal of antibiotic drugs during the first 8 hours of combined continuous renal replacement therapy and cytosorb adsorption | Removal of antibiotic drugs during combined CRRT and adsorption will be evaluated by calculating total filter clearance using the drug concentration pre- and postfilter as well as the dialysate concentration. The adsorptive clearance will be evaluated using the pre- and postadsorber concentration. The outcome measure will be removal of antibiotic drug [mg/8 h dosing interval]. | 8 hours |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Critically ill patients treated for sepsis on surgical intensive care unit undergoing renal replacement therapy.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Detlef Kindgen-Milles, Prof. | Contact | +49 211 81 | 07047 | Kindgen-Milles@med.uni-duesseldorf.de |
| Name | Affiliation | Role |
|---|---|---|
| Detlef Kindgen-Milles, Prof. | Department of Anesthesiology, Duesseldorf University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Interdisziplinäre Intensivstation ZOM 1, UKD | Recruiting | Düsseldorf | 40225 | Germany |
Not provided
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| D018805 | Sepsis |
| D058186 | Acute Kidney Injury |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |